Logisil Capsule contains Calcium Dobesilate 500mg, a vasoactive agent primarily used to improve microcirculation and reduce capillary permeability. It is indicated for the treatment of chronic venous insufficiency, diabetic retinopathy, and hemorrhoidal disease. Calcium Dobesilate acts by stabilizing capillary walls, decreasing capillary fragility, and inhibiting platelet aggregation, thereby enhancing blood flow and reducing edema and inflammation in affected tissues. The capsule formulation ensures accurate dosing and ease of administration. Logisil is commonly prescribed to alleviate symptoms such as leg swelling, pain, and heaviness associated with venous disorders, as well as to prevent progression of diabetic microangiopathy by protecting retinal capillaries. Clinical studies have demonstrated its efficacy in improving venous tone and microvascular function, contributing to symptom relief and improved quality of life. The medication is generally well tolerated, with adverse effects being rare and typically mild, including gastrointestinal discomfort or allergic reactions. It is contraindicated in patients with known hypersensitivity to Calcium Dobesilate or any capsule excipients. Dosage and duration of therapy should be individualized based on the clinical condition and physician’s assessment. Logisil Capsule should be used under medical supervision to ensure optimal therapeutic outcomes.